Patents by Inventor Andreas Loew

Andreas Loew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11291721
    Abstract: Multispecific molecules that include i) a tumor-targeting moiety; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 5, 2022
    Assignee: Marengo Therapeutics, Inc.
    Inventors: Andreas Loew, Brian Edward Vash
  • Publication number: 20220064255
    Abstract: The disclosure provides methods of expanding T cells ex vivo comprising contacting the T cells with antibody molecules that bind to TCR V? regions. In some embodiments, the T cells comprise one or more nucleic acid molecule encoding an exogenous cellular receptor, for example, a chimeric antigen receptor (CAR) or an exogenous T cell receptor (TCR).
    Type: Application
    Filed: July 2, 2021
    Publication date: March 3, 2022
    Inventors: Andreas Loew, Stephen Arkinstall
  • Publication number: 20220064297
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 3, 2022
    Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
  • Publication number: 20210380692
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating an infectious disease using the aforesaid molecules.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 9, 2021
    Inventors: Andreas Loew, Seng-Lai Tan, Jonathan Hsu, Brian Edward Vash
  • Publication number: 20210380691
    Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a TCR variable beta chain (TCRBV) antigen; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or cytokine inhibitor molecule; and/or (iv) a death receptor signal enhancer. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating autoimmune diseases using the aforesaid molecules.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 9, 2021
    Inventors: Andreas Loew, Seng-Lai Tan, Jonathan Hsu, Brian Edward Vash, Stephanie J. Maiocco, Nidhi Malhotra, Madan Katragadda
  • Publication number: 20210380682
    Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a T cell receptor beta chain constant domain 1 or T cell receptor beta chain constant domain 2; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or cytokine inhibitor molecule; (iv) a death receptor signal enhancer; and/or (v) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 9, 2021
    Inventors: Andreas Loew, Nidhi Malhotra, Madan Katragadda, Seng-Lai Tan, Jonathan Hsu, Brian Edward Vash, Stephanie J. Maiocco, Peter Marek, Gurkan Guntas
  • Publication number: 20210380670
    Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 9, 2021
    Inventors: Andreas Loew, Ilaria Lamberto, Seng-Lai Tan, Jonathan Hsu, Brian Edward Vash, Nidhi Malhotra, Madan Katragadda, John Leonard Herrmann, Stephanie J. Maiocco
  • Publication number: 20210371523
    Abstract: Antibody molecules that specifically bind to NKp30 are disclosed. The anti-NKp30 antibody molecules can be used to treat, prevent and/or diagnose cancerous, autoimmune or infectious conditions and disorders.
    Type: Application
    Filed: August 13, 2021
    Publication date: December 2, 2021
    Inventors: Andreas Loew, Nidhi Malhotra, Madan Katragadda, Brian Edward Vash, Stephanie J. Maiocco
  • Patent number: 11149076
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 19, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Publication number: 20210284752
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Application
    Filed: December 23, 2020
    Publication date: September 16, 2021
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • Publication number: 20210277119
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: July 3, 2019
    Publication date: September 9, 2021
    Inventors: Seng-Lai TAN, Brian Edward VASH, Jonathan HSU, Dilini Charmain GUNASEKERA, Sangeetha Sagar PALAKURTHI, Andreas LOEW
  • Publication number: 20210246227
    Abstract: Molecules that bind myeloproliferative leukemia (MPL) protein and methods of using the same are disclosed.
    Type: Application
    Filed: May 31, 2018
    Publication date: August 12, 2021
    Inventors: Andreas Loew, Brian Edward Vash
  • Publication number: 20210238280
    Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin mutant protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or a modulator of a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 5, 2021
    Inventors: Andreas Loew, Ilaria Lamberto, John Leonard Herrmann, Brian Edward Vash
  • Patent number: 11028177
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, Carl H. June, Michael D. Kalos, Andreas Loew, John Scholler
  • Publication number: 20210137982
    Abstract: Provided herein are nucleic acid constructs, polypeptides and T cells related to antigen binding domains that bind to mutant calreticulin; and methods of use thereof for the treatment of diseases, including cancer.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 13, 2021
    Inventors: Andreas LOEW, Brian Edward VASH
  • Publication number: 20210087279
    Abstract: Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
    Type: Application
    Filed: July 28, 2020
    Publication date: March 25, 2021
    Inventors: Boris Engels, Andreas Loew, Michael C. Milone, Li Zhou
  • Patent number: 10927184
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: February 23, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • Publication number: 20210009711
    Abstract: Multispecific molecules that include a first tumor-targeting moiety; a second tumor-targeting moiety; and one, two or all of: an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); a cytokine molecule or a modulator of a cytokine molecule; and/or a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 14, 2021
    Inventors: Andreas Loew, Ilaria Lamberto, John Leonard Herrmann, Brian Edward Vash
  • Publication number: 20210002377
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
    Type: Application
    Filed: May 27, 2020
    Publication date: January 7, 2021
    Inventors: Jennifer Brogdon, Saar Gill, David Jonathan Glass, Saad Kenderian, Andreas Loew, Joan Mannick, Michael C. Milone, Leon Murphy, David L. Porter, Marco Ruella, Yongqiang Wang, Qilong Wu, Jiquan Zhang
  • Publication number: 20200407460
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: January 23, 2020
    Publication date: December 31, 2020
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu